Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register
Summary The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide therapeutic decisions. However, few population‐based studies have compared the value of the different scoring systems. With data from the nati...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2018-06, Vol.181 (5), p.614-627 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 627 |
|---|---|
| container_issue | 5 |
| container_start_page | 614 |
| container_title | British journal of haematology |
| container_volume | 181 |
| creator | Moreno Berggren, Daniel Folkvaljon, Yasin Engvall, Marie Sundberg, Johan Lambe, Mats Antunovic, Petar Garelius, Hege Lorenz, Fryderyk Nilsson, Lars Rasmussen, Bengt Lehmann, Sören Hellström‐Lindberg, Eva Jädersten, Martin Ejerblad, Elisabeth |
| description | Summary
The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide therapeutic decisions. However, few population‐based studies have compared the value of the different scoring systems. With data from the nationwide Swedish population‐based MDS register we validated the International Prognostic Scoring System (IPSS), revised IPSS (IPSS‐R) and the World Health Organization (WHO) Classification‐based Prognostic Scoring System (WPSS). We also present population‐based data on incidence, clinical characteristics including detailed cytogenetics and outcome from the register. The study encompassed 1329 patients reported to the register between 2009 and 2013, 14% of these had therapy‐related MDS (t‐MDS). Based on the MDS register, the yearly crude incidence of MDS in Sweden was 2·9 per 100 000 inhabitants. IPSS‐R had a significantly better prognostic power than IPSS (P |
| doi_str_mv | 10.1111/bjh.15243 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_488756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2045952897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5763-27b00328446001dd9757c90d9a3a0ef29a66d819a6685b861ce8843291f58ba53</originalsourceid><addsrcrecordid>eNqNks1u1DAQgC0EosvCgRdAlri0Emn9E8c2t9ICBRWBVOBqOYmz6yWJgx1rlRsnzjwjT4KXLEVCKqovY3k-fx7bA8BjjI5xGiflZn2MGcnpHbDAtGAZwTm-CxYIIZ5hlIsD8CCEDUKYIobvgwMiOeK8kAvw_YN3q96F0VYwVM7bfgXDFEbTBdg4D7vJtK6ewtDqmZn62rvOBHj47vzqCNoeaji4IbZ6tK7_-e1HqYOpYTDjmFzPU9abwfkRNmkbHNcGXm1NbcMapv0pt7LpMP8Q3Gt0G8yjfVyCT69efjy7yC7fv35zdnqZVYwXNCO8RIgSkedFukxdS854JVEtNdXINETqoqgF3gXBSlHgygiRUyJxw0SpGV2CbPaGrRliqQZvO-0n5bRV-6UvaWZULgRnReKf3cif28-nyvmVilFRxjkm_9X_xbuoMEO7wm6ldz6qglOa307f2qTPJeW7cg5nfvDuazRhVJ0NlWlb3RsXgyLpLbmUJNFL8PQfdOOi79NfJCpnkhEheaKOZqryLgRvmusSMFK7VlSpFdXvVkzsk70xlp2pr8k_vZeAkxnY2tZMN5vUi7cXs_IXOsvp_A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2045952897</pqid></control><display><type>article</type><title>Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Moreno Berggren, Daniel ; Folkvaljon, Yasin ; Engvall, Marie ; Sundberg, Johan ; Lambe, Mats ; Antunovic, Petar ; Garelius, Hege ; Lorenz, Fryderyk ; Nilsson, Lars ; Rasmussen, Bengt ; Lehmann, Sören ; Hellström‐Lindberg, Eva ; Jädersten, Martin ; Ejerblad, Elisabeth</creator><creatorcontrib>Moreno Berggren, Daniel ; Folkvaljon, Yasin ; Engvall, Marie ; Sundberg, Johan ; Lambe, Mats ; Antunovic, Petar ; Garelius, Hege ; Lorenz, Fryderyk ; Nilsson, Lars ; Rasmussen, Bengt ; Lehmann, Sören ; Hellström‐Lindberg, Eva ; Jädersten, Martin ; Ejerblad, Elisabeth</creatorcontrib><description>Summary
The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide therapeutic decisions. However, few population‐based studies have compared the value of the different scoring systems. With data from the nationwide Swedish population‐based MDS register we validated the International Prognostic Scoring System (IPSS), revised IPSS (IPSS‐R) and the World Health Organization (WHO) Classification‐based Prognostic Scoring System (WPSS). We also present population‐based data on incidence, clinical characteristics including detailed cytogenetics and outcome from the register. The study encompassed 1329 patients reported to the register between 2009 and 2013, 14% of these had therapy‐related MDS (t‐MDS). Based on the MDS register, the yearly crude incidence of MDS in Sweden was 2·9 per 100 000 inhabitants. IPSS‐R had a significantly better prognostic power than IPSS (P < 0·001). There was a trend for better prognostic power of IPSS‐R compared to WPSS (P = 0·05) and for WPSS compared to IPSS (P = 0·07). IPSS‐R was superior to both IPSS and WPSS for patients aged ≤70 years. Patients with t‐MDS had a worse outcome compared to de novo MDS (d‐MDS), however, the validity of the prognostic scoring systems was comparable for d‐MDS and t‐MDS. In conclusion, population‐based studies are important to validate prognostic scores in a ‘real‐world’ setting. In our nationwide cohort, the IPSS‐R showed the best predictive power.</description><identifier>ISSN: 0007-1048</identifier><identifier>ISSN: 1365-2141</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.15243</identifier><identifier>PMID: 29707769</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Cytogenetics ; Hematology ; Incidence ; International Prognostic Scoring System ; Myelodysplastic syndrome ; Population ; Population studies ; revised International Prognostic Scoring System ; Risk assessment ; therapy-related myelodysplastic syndrome ; WHO Classification-based Prognostic Scoring System</subject><ispartof>British journal of haematology, 2018-06, Vol.181 (5), p.614-627</ispartof><rights>2018 John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons Ltd.</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5763-27b00328446001dd9757c90d9a3a0ef29a66d819a6685b861ce8843291f58ba53</citedby><cites>FETCH-LOGICAL-c5763-27b00328446001dd9757c90d9a3a0ef29a66d819a6685b861ce8843291f58ba53</cites><orcidid>0000-0002-4198-4945</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.15243$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.15243$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29707769$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-149372$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-67334$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-150884$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-357712$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:138381440$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreno Berggren, Daniel</creatorcontrib><creatorcontrib>Folkvaljon, Yasin</creatorcontrib><creatorcontrib>Engvall, Marie</creatorcontrib><creatorcontrib>Sundberg, Johan</creatorcontrib><creatorcontrib>Lambe, Mats</creatorcontrib><creatorcontrib>Antunovic, Petar</creatorcontrib><creatorcontrib>Garelius, Hege</creatorcontrib><creatorcontrib>Lorenz, Fryderyk</creatorcontrib><creatorcontrib>Nilsson, Lars</creatorcontrib><creatorcontrib>Rasmussen, Bengt</creatorcontrib><creatorcontrib>Lehmann, Sören</creatorcontrib><creatorcontrib>Hellström‐Lindberg, Eva</creatorcontrib><creatorcontrib>Jädersten, Martin</creatorcontrib><creatorcontrib>Ejerblad, Elisabeth</creatorcontrib><title>Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide therapeutic decisions. However, few population‐based studies have compared the value of the different scoring systems. With data from the nationwide Swedish population‐based MDS register we validated the International Prognostic Scoring System (IPSS), revised IPSS (IPSS‐R) and the World Health Organization (WHO) Classification‐based Prognostic Scoring System (WPSS). We also present population‐based data on incidence, clinical characteristics including detailed cytogenetics and outcome from the register. The study encompassed 1329 patients reported to the register between 2009 and 2013, 14% of these had therapy‐related MDS (t‐MDS). Based on the MDS register, the yearly crude incidence of MDS in Sweden was 2·9 per 100 000 inhabitants. IPSS‐R had a significantly better prognostic power than IPSS (P < 0·001). There was a trend for better prognostic power of IPSS‐R compared to WPSS (P = 0·05) and for WPSS compared to IPSS (P = 0·07). IPSS‐R was superior to both IPSS and WPSS for patients aged ≤70 years. Patients with t‐MDS had a worse outcome compared to de novo MDS (d‐MDS), however, the validity of the prognostic scoring systems was comparable for d‐MDS and t‐MDS. In conclusion, population‐based studies are important to validate prognostic scores in a ‘real‐world’ setting. In our nationwide cohort, the IPSS‐R showed the best predictive power.</description><subject>Cytogenetics</subject><subject>Hematology</subject><subject>Incidence</subject><subject>International Prognostic Scoring System</subject><subject>Myelodysplastic syndrome</subject><subject>Population</subject><subject>Population studies</subject><subject>revised International Prognostic Scoring System</subject><subject>Risk assessment</subject><subject>therapy-related myelodysplastic syndrome</subject><subject>WHO Classification-based Prognostic Scoring System</subject><issn>0007-1048</issn><issn>1365-2141</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNks1u1DAQgC0EosvCgRdAlri0Emn9E8c2t9ICBRWBVOBqOYmz6yWJgx1rlRsnzjwjT4KXLEVCKqovY3k-fx7bA8BjjI5xGiflZn2MGcnpHbDAtGAZwTm-CxYIIZ5hlIsD8CCEDUKYIobvgwMiOeK8kAvw_YN3q96F0VYwVM7bfgXDFEbTBdg4D7vJtK6ewtDqmZn62rvOBHj47vzqCNoeaji4IbZ6tK7_-e1HqYOpYTDjmFzPU9abwfkRNmkbHNcGXm1NbcMapv0pt7LpMP8Q3Gt0G8yjfVyCT69efjy7yC7fv35zdnqZVYwXNCO8RIgSkedFukxdS854JVEtNdXINETqoqgF3gXBSlHgygiRUyJxw0SpGV2CbPaGrRliqQZvO-0n5bRV-6UvaWZULgRnReKf3cif28-nyvmVilFRxjkm_9X_xbuoMEO7wm6ldz6qglOa307f2qTPJeW7cg5nfvDuazRhVJ0NlWlb3RsXgyLpLbmUJNFL8PQfdOOi79NfJCpnkhEheaKOZqryLgRvmusSMFK7VlSpFdXvVkzsk70xlp2pr8k_vZeAkxnY2tZMN5vUi7cXs_IXOsvp_A</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Moreno Berggren, Daniel</creator><creator>Folkvaljon, Yasin</creator><creator>Engvall, Marie</creator><creator>Sundberg, Johan</creator><creator>Lambe, Mats</creator><creator>Antunovic, Petar</creator><creator>Garelius, Hege</creator><creator>Lorenz, Fryderyk</creator><creator>Nilsson, Lars</creator><creator>Rasmussen, Bengt</creator><creator>Lehmann, Sören</creator><creator>Hellström‐Lindberg, Eva</creator><creator>Jädersten, Martin</creator><creator>Ejerblad, Elisabeth</creator><general>Blackwell Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG8</scope><scope>D91</scope><scope>D93</scope><scope>DF2</scope><orcidid>https://orcid.org/0000-0002-4198-4945</orcidid></search><sort><creationdate>201806</creationdate><title>Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register</title><author>Moreno Berggren, Daniel ; Folkvaljon, Yasin ; Engvall, Marie ; Sundberg, Johan ; Lambe, Mats ; Antunovic, Petar ; Garelius, Hege ; Lorenz, Fryderyk ; Nilsson, Lars ; Rasmussen, Bengt ; Lehmann, Sören ; Hellström‐Lindberg, Eva ; Jädersten, Martin ; Ejerblad, Elisabeth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5763-27b00328446001dd9757c90d9a3a0ef29a66d819a6685b861ce8843291f58ba53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cytogenetics</topic><topic>Hematology</topic><topic>Incidence</topic><topic>International Prognostic Scoring System</topic><topic>Myelodysplastic syndrome</topic><topic>Population</topic><topic>Population studies</topic><topic>revised International Prognostic Scoring System</topic><topic>Risk assessment</topic><topic>therapy-related myelodysplastic syndrome</topic><topic>WHO Classification-based Prognostic Scoring System</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreno Berggren, Daniel</creatorcontrib><creatorcontrib>Folkvaljon, Yasin</creatorcontrib><creatorcontrib>Engvall, Marie</creatorcontrib><creatorcontrib>Sundberg, Johan</creatorcontrib><creatorcontrib>Lambe, Mats</creatorcontrib><creatorcontrib>Antunovic, Petar</creatorcontrib><creatorcontrib>Garelius, Hege</creatorcontrib><creatorcontrib>Lorenz, Fryderyk</creatorcontrib><creatorcontrib>Nilsson, Lars</creatorcontrib><creatorcontrib>Rasmussen, Bengt</creatorcontrib><creatorcontrib>Lehmann, Sören</creatorcontrib><creatorcontrib>Hellström‐Lindberg, Eva</creatorcontrib><creatorcontrib>Jädersten, Martin</creatorcontrib><creatorcontrib>Ejerblad, Elisabeth</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Linköpings universitet</collection><collection>SWEPUB Örebro universitet</collection><collection>SWEPUB Umeå universitet</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreno Berggren, Daniel</au><au>Folkvaljon, Yasin</au><au>Engvall, Marie</au><au>Sundberg, Johan</au><au>Lambe, Mats</au><au>Antunovic, Petar</au><au>Garelius, Hege</au><au>Lorenz, Fryderyk</au><au>Nilsson, Lars</au><au>Rasmussen, Bengt</au><au>Lehmann, Sören</au><au>Hellström‐Lindberg, Eva</au><au>Jädersten, Martin</au><au>Ejerblad, Elisabeth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2018-06</date><risdate>2018</risdate><volume>181</volume><issue>5</issue><spage>614</spage><epage>627</epage><pages>614-627</pages><issn>0007-1048</issn><issn>1365-2141</issn><eissn>1365-2141</eissn><abstract>Summary
The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide therapeutic decisions. However, few population‐based studies have compared the value of the different scoring systems. With data from the nationwide Swedish population‐based MDS register we validated the International Prognostic Scoring System (IPSS), revised IPSS (IPSS‐R) and the World Health Organization (WHO) Classification‐based Prognostic Scoring System (WPSS). We also present population‐based data on incidence, clinical characteristics including detailed cytogenetics and outcome from the register. The study encompassed 1329 patients reported to the register between 2009 and 2013, 14% of these had therapy‐related MDS (t‐MDS). Based on the MDS register, the yearly crude incidence of MDS in Sweden was 2·9 per 100 000 inhabitants. IPSS‐R had a significantly better prognostic power than IPSS (P < 0·001). There was a trend for better prognostic power of IPSS‐R compared to WPSS (P = 0·05) and for WPSS compared to IPSS (P = 0·07). IPSS‐R was superior to both IPSS and WPSS for patients aged ≤70 years. Patients with t‐MDS had a worse outcome compared to de novo MDS (d‐MDS), however, the validity of the prognostic scoring systems was comparable for d‐MDS and t‐MDS. In conclusion, population‐based studies are important to validate prognostic scores in a ‘real‐world’ setting. In our nationwide cohort, the IPSS‐R showed the best predictive power.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>29707769</pmid><doi>10.1111/bjh.15243</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-4198-4945</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2018-06, Vol.181 (5), p.614-627 |
| issn | 0007-1048 1365-2141 1365-2141 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_488756 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete |
| subjects | Cytogenetics Hematology Incidence International Prognostic Scoring System Myelodysplastic syndrome Population Population studies revised International Prognostic Scoring System Risk assessment therapy-related myelodysplastic syndrome WHO Classification-based Prognostic Scoring System |
| title | Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A59%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20scoring%20systems%20for%20myelodysplastic%20syndromes%20(MDS)%20in%20a%20population%E2%80%90based%20setting:%20a%20report%20from%20the%20Swedish%20MDS%20register&rft.jtitle=British%20journal%20of%20haematology&rft.au=Moreno%20Berggren,%20Daniel&rft.date=2018-06&rft.volume=181&rft.issue=5&rft.spage=614&rft.epage=627&rft.pages=614-627&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.15243&rft_dat=%3Cproquest_swepu%3E2045952897%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2045952897&rft_id=info:pmid/29707769&rfr_iscdi=true |